Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.51 |
| ▸ | PDE1A | P54750 | 1/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.51 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7441718 | 0.88 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL201799 | 0.88 | PDE4B (0.52) | PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL202832 | 0.87 | PDE4B (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2693669 | 0.85 | HRH3 (0.61) | PDE4B | |
| SCHEMBL7445077 | 0.85 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7920336 | 0.84 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL7338297 | 0.84 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL1560104 | 0.82 | PDE4B (0.45) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1157568 | 0.82 | POLB (0.51) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7360862 | 0.81 | PDE4D (0.54) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015225-A1 | Dimeric Piperidine Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| EP-1786775-A1 | DIMERIC PIPERIDINE DERIVATES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006008260-A1 | DIMERIC PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-26 | — | — | WO | disclosed |
| EP-0652868-B1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE | AVENTIS PHARMA LTD (GB) | 2004-11-10 | — | — | EP | disclosed |
| EP-0928789-B1 | 6-PHENYLTETRAHYDRO-1,3-OXAZIN-2-ONE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | NIKKEN CHEMICALS CO LTD (JP) | 2004-09-29 | — | — | EP | disclosed |
| EP-0626939-B1 | TRI-SUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 2001-11-07 | — | — | EP | disclosed |
| US-6255326-B1 | ANTIINFLAMMATORY AGENT; AUTOIMMUNE DISEASES | AVENTIS PHARMA LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| US-6251897-B1 | TREATING DERMATITIS, ASTHMA | NIKKEN CHEMICALS CO., LTD (JP) | 2001-06-26 | — | — | US | disclosed |
| US-6096768-A | ADMINISTERING A 3, 5, 6-SUBSTITUTED PHENYL COMPOUND FOR THE TREATMENT OF INFLAMMATION AND AUTOIMMUNE DISORDERS | RHONE-POULENC RORER LIMITED (GB) | 2000-08-01 | — | — | US | disclosed |
| US-5935978-A | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group | RHONE-POULENC RORER LIMITED (GB) | 1999-08-10 | — | — | US | disclosed |
| EP-0741707-B1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE POULENC RORER LTD (GB) | 1998-04-01 | — | — | EP | disclosed |
| WO-1998008830-A1 | THIAZOLE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE-IV | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-03-05 | — | — | WO | disclosed |
| US-5698711-A | INHIBITORS OF TUMOR NECROSIS FACTOR, CYCLIC ADENOSINE-3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE AND EOSINOPHILS | RHONE-POULENC RORER LIMITED (GB) | 1997-12-16 | — | — | US | disclosed |
| US-5679696-A | FOR INHIBITING TUMOR NECROSIS FACTOR; ENZYME INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1997-10-21 | — | — | US | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
| EP-0652868-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1995-05-17 | — | — | EP | disclosed |
| EP-0626939-A1 | TRI-SUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1994-12-07 | — | — | EP | disclosed |
| WO-1994014742-A1 | TRI-SUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CELLTECH LIMITED (GB) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015225-A1 | Dimeric Piperidine Derivatives | PTGER4, PTGER3, PTGER1 | PDE4A 2638/4885PDE4B 3307/4885PDE4C 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.